Biotechnology company Active Biotech AB (STO:ACTI) on Thursday reported loss after tax of SEK108.8m, or SEK1.12 per share, for 2017, from January 2017 to December 2017.
This was a decline over loss after tax of SEK59.6m, or SEK0.65 per share, in 2016. Reportedly, loss for 2017 includes write down of property of SEK50m.
Net sales for the year were SEK20.2m, as compared with SEK19.0m in 2016.
The board of directors has proposed a new share issue of approximately SEK48m, with pre-emptive rights for the shareholders
In connection with the new share issue, the company has received a permanent waiver from its commitment to the bank that finances the company's property in Lund that the company's liquidity should never fall below MSEK30m.
Active Biotech clarified that it again has funding for the coming 12 month period.
Active Biotech focuses on research and development of pharmaceuticals and vaccines. The company is developing products designed to treat a variety of diseases including multiple sclerosis, lung, renal and pancreatic cancer.
(EUR1.00=SEK9.92)
Pfizer reports positive Phase 3 data for ABRYSVO in adults at risk for RSV disease
D3 Bio announces Series A+ Round completion to advance innovative oncology pipeline
Dizal's sunvozertinib receives US FDA Breakthrough Therapy Designation
Merck launches Phase 3 trial of MK-1084 and KEYTRUDA combination in metastatic NSCLC
Trevi Therapeutics names new vice president of Clinical Development
Personalis validates NeXT Personal test for ultra-sensitive MRD detection
Merck reports lung cancer trial failed to meet endpoints
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib